INS and heart failure: With the increasing prevalence of heart failure and a shortage of donor organs,the number of patients who may benefit from durable mechanical circulatorysupport continues to grow, especially in the indication of destination therapy.Therefore, it is necessary to fully understand metabolic changes that may occurafter the implantation of a durable left ventricular assist device and the impactof current heart failure pharmacotherapy (i.e., SGLT2i on body mass and arterialpressure reduction, improvement of insulin sensitivity, etc.).